- Tools
- Downloads
- Links
- Community
- About
- Help
FB2026_01
,
released March 12, 2026
[68F1-68F1];[68F2-68F2];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
68F1;68F2
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Inferred to overlap with: Df(3L)BSC840.
Inferred to overlap with: Df(3L)BSC574.
Df(3L)BSC395 homozygous embryos show a regular muscle pattern but the segmental border muscles are reduced to mini muscles and some unfused myoblasts are visible, as compared to controls.
The presence of P+PBac{XP5.RB3}BSC395 was verified using the PCR methods and primers described in FBrf0175003, with the substitution of the primer 5'-CCAATGCGTTTATTTCAGGTCACG-3' for the RB3' plus or RB3' minus primer in the Hybrid PCR protocol in the Supplementary Methods.
Exelixis, Inc. determined the insertion site of the progenitor P{XP}d03723 to be at Release 3 genomic coordinate 12039353 on chromosome arm 3L. The Gene Disruption project determined the insertion site of the progenitor P{XP}d03723 to be at Release 3 genomic coordinate 12039369 on arm 3L. This corresponds to 68F2 on both the Release 3 and 5 genome maps. The predicted position of the progenitor PBac{RB}CG6928e01931 on the Release 5 map is 68F1. Consequently, the cytological breakpoints of Df(3L)BSC395 are predicted to be 68F1;68F2.